ストックスクリーナーアプリを入手
198.99
1.86%
-3.77
Resmed Inc (RMD) 最新ニュース
ResMed stock trades steady as sleep apnea demand supports earnings - ad-hoc-news.de
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276 - Moomoo
Resmed to sell MatrixCare business to PE firm Frazier Healthcare Partners - DOTmed
ResMed stock stabilizes as investors weigh recent growth and margin trends - ad-hoc-news.de
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed downgraded at RBC Capital Markets on FY27 challenges - MSN
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
FDA issues early alert for certain Resmed Astral ventilators - MassDevice
How much could ResMed shares rise according to Morgans? - The Motley Fool Australia
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating - Moomoo
ResMed shares rise over 3% as $490 million MatrixCare divestment fuels buybacks - Traders Union
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
Why Is ResMed Stock Down Today? - Kalkine
Health Check: Restless investors question sleep giant Resmed’s short-term prospects - Stockhead
ResMed (ASX:RMD) Falls — What Is Behind the Medical Device Giant’s Session Decline? - Kalkine
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset? - Kalkine Media
ResMed Price Target Cut 1.8% to A$40.97/Share by Morgans - Moomoo
Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges - TradingView
Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges - PR Newswire
Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34 - Moomoo
Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270 - Moomoo
ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup - Moomoo
ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews
ResMed stock reflects steady demand for sleep apnea solutions - ad-hoc-news.de
Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 - marketscreener.com
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed Stock Sinks as Citi Sounds Supply Alarm - TipRanks
ResMed Inc. stock falls Wednesday, underperforms market - MSN
In an era of ‘baddies,’ companies are racing to keep up with the influencer economy - CNN
How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - Sahm
ResMed (RMD) Divestiture of MatrixCare presentation Summary - Quartr
ResMed Is Maintained at Hold by Jefferies - Moomoo
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - Yahoo Finance
Jefferies Adjusts Price Target on ResMed to $225 From $240 - marketscreener.com
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health - Yahoo Finance
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Ord Minnett - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie - The Globe and Mail
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact - simplywall.st
ResMed Analyst Backs Portfolio Reset - Benzinga
ResMed's Q4 2026 Earnings: What to Expect - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and ResMed - Yahoo Finance
What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares? - Kalkine
Form 4 ResMed Inc For: 9 July By Investing.com - Investing.com Nigeria
ResMed chairman & CEO Michael Farrell sells $1.09m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing - marketscreener.com
ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan - Stock Titan
ResMed Inc. highlights sleep and respiratory focus as investors track Nasdaq-listed shares - Ad-hoc-news.de
ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says - marketscreener.com
ResMed to sell MatrixCare business to Frazier Healthcare Partners - MSN
ResMed's billion-dollar blowup - intelligentinvestor.com.au
ResMed's $490M Sale Looks Strategically Sound -- Market Talk - Moomoo
ResMed Willing to Cut Underperforming Assets -- Market Talk - Moomoo
1.16%
大文字化:
|
ボリューム (24 時間):